drugset / Trial / NCT04764474
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
NaSingle-groupOpen-labelTreatment
Summary
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Timeline
- Start
- 2021-04-12
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
Outcome
Outcome not reported
Stopped (Business): “The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RANOSIDENIB | Small molecule | — | Oral |
Indications
No indication recorded.